$10.17
+0.78 (+8.31%)
ABSI News2 articles
AbCellera Shares Jump 9.7% Ahead of Key Phase 2 Data Release
AbCellera (ABCL) rose 9.7% after hours as investors await Phase 2 data for ABCL635, set to release Monday. The surge adds ~$205M to market cap.
Absci Surges on Positive Phase 1 Data for Hair Loss Drug and $100M Capital Raise
Absci shares soared 35% to $10.01 after early Phase 1 safety data for its hair-loss antibody ABS-201 showed no serious adverse events, and the company raised $100 million in a stock offering.